Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
Bought 35.0K
Bought 15.0K
Bought 9.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Durso Jerome BenedictPresident and CEO, Director · 2 transactions | +280% | 47.5K | — | 35.0K | — |
| Weaver Gregory LChief Financial Officer · 2 transactions | +32.4% | 38.1K | — | 15.0K | — |
| Gill JohnDirector · 1 transaction | +73.6% | 21.7K | — | 9.2K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: +59.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.